Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008).
DRUG INFORMATION ASSOCIATION (DIA) POSTPONES 3RD ANNUAL CONFERENCE ON DRUG DISCOVERY AND CLINICAL DEVELOPMENT IN INDIA
WHO:
Drug Information Association (DIA)
WHAT:
3rd Annual Conference on Drug Discovery and Clinical Development in India
WHERE:
Renaissance Mumbai Hotel and Convention Centre
Mumbai, India
WHEN:
December 7-10, 2008
WHY:
Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008). The DIA Board of Directors, operational staff, and members and volunteers express their sympathies to the many people affected by the past week’s events. DIA is currently making plans to present this conference in February 2009 and will contact you with updated information about specific dates as soon as this information becomes available.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.